Klöppel Günter, La Rosa Stefano
Institute of Pathology, Consultation Center for Pancreatic and Endocrine Tumors, Technical University of Munich, Trogerstr. 18, 81675, Munich, Germany.
Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Virchows Arch. 2018 Mar;472(3):341-349. doi: 10.1007/s00428-017-2258-0. Epub 2017 Nov 13.
In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where the antibody was produced in the university department of pathology and refers to the number of the original clone (67). Systematic assessment of the proliferative activity of tumors using Ki67 started in the 1990s, when Ki67, which only worked on frozen tissue, was complemented by the antibody MIB-1 that also worked in formalin-fixed tissues. Pancreatic neuroendocrine neoplasms (PanNENs) were the first endocrine tumors whose proliferative activity was assessed with Ki67. This approach was so successful that Ki67 was included as prognostic marker in the 2000 and 2004 WHO classifications of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In 2010, the WHO classification of GEP-NENs introduced a three-tiered grading, originally proposed by ENETS in 2006 that was mainly based on the Ki67 index. As it has subsequently been shown that the Ki67 index is the most reliable factor in the prognostic evaluation of GEP-NENs, especially of PanNENs, the 2017 WHO classification of PanNENs requires its use and strongly recommends exact assessment of the proportion Ki67-labeled cells as basis for the calculation of the Ki67 index. Problems in assessing the Ki67 index include intertumoral and intratumoral staining heterogeneity and counting methods. Despite such problems, the Ki67 index has emerged as indispensable for the prognostic and therapeutic stratification of the majority of GEP-NENs and can barely be replaced by counting mitoses. In future, however, it can be anticipated that the Ki67 cut-offs experience refinement in relation to the type of tumor, its location, and its response to therapy. It is also possible that the prognostic risk of an individual tumor is calculated for each Ki67 unit and not for an "a priori" fixed Ki67 class.
1983年,一种名为Ki67的单克隆抗体被研制出来,它能够标记增殖的非肿瘤细胞和肿瘤细胞的细胞核。Ki67这个名字来源于基尔市(Ki),该抗体是在该市大学病理系生产的,同时也代表了原始克隆的编号(67)。20世纪90年代开始使用Ki67对肿瘤的增殖活性进行系统评估,当时只能用于冷冻组织的Ki67,被同样适用于福尔马林固定组织的抗体MIB-1所补充。胰腺神经内分泌肿瘤(PanNENs)是最早用Ki67评估其增殖活性的内分泌肿瘤。这种方法非常成功,以至于Ki67被纳入2000年和2004年世界卫生组织(WHO)胃肠胰腺神经内分泌肿瘤(GEP-NENs)的分类中作为预后标志物。2010年,WHO对GEP-NENs的分类引入了三级分级,最初由欧洲神经内分泌肿瘤学会(ENETS)在2006年提出,主要基于Ki67指数。随后有研究表明,Ki67指数是GEP-NENs,尤其是PanNENs预后评估中最可靠的因素,因此2017年WHO对PanNENs的分类要求使用该指标,并强烈建议精确评估Ki67标记细胞的比例作为计算Ki67指数的基础。评估Ki67指数存在的问题包括肿瘤间和肿瘤内染色异质性以及计数方法。尽管存在这些问题,Ki67指数已成为大多数GEP-NENs预后和治疗分层中不可或缺的指标,几乎无法用有丝分裂计数来替代。然而,未来可以预期,Ki67的临界值将根据肿瘤类型、位置及其对治疗的反应进行细化。也有可能针对每个Ki67单位而非“先验”固定的Ki67类别来计算单个肿瘤的预后风险。